Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON22353Phase 2Active, not recruiting
Phase 2, open-label trial of capecitabine and oxaliplatin in colorectal cancer (CRC) and peritoneal carcinomatosis (PC), sponsored by University Medical Center Groningen. Primary endpoint: Complete cytoreduction rate. Started Apr 2013; status: active, not recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON22353.